BioNano Genomics Inc vs Prudential Financial Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Prudential Financial Inc trades at $123 (market cap $42.20B). The key difference: Prudential Financial Inc is far larger — about 3089.3× BioNano Genomics Inc's market cap, and Prudential Financial Inc pays a 4.58% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PRU | |
|---|---|---|
Market Cap | $13.66M | $42.20B |
Sector | Health | Financials |
52-Week High | $4.92 | $123.93 |
52-Week Low | $1.06 | $92.00 |
Enterprise Value | $16.26M | $70.98B |
Dividend Yield | — | 4.58% |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Prudential Financial (PRU) trades at $122.63, up 0.43% on the day, with a bullish technical signal from moving averages and recent earnings beats in Q1 and Q2 2026. The company reported Q2 EPS of $4.08, exceeding expectations, driven by strength in PGIM and international segments. Valuation remains attractive with a P/E of 11.09 and P/S of 0.66, while a $1.40 quarterly dividend supports income appeal.
Outlook is cautiously optimistic given earnings momentum and strategic focus on capital-light operations, but risks include sensitivity to interest rates and regulatory changes in key markets like China. Analyst consensus is mixed with a Hold rating predominating, though institutional holdings show increased interest, suggesting potential for upside if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →